(Circulation. 1997;96:1914-1922.)
© 1997 American Heart Association, Inc.
Articles |
ß2-Adrenergic Receptor Antagonists Protect Against Ventricular Fibrillation
In Vivo and In Vitro Evidence for Enhanced Sensitivity to ß2-Adrenergic Stimulation in Animals Susceptible to Sudden Death
From the Departments of Physiology and Medical Biochemistry, Ohio State University, Columbus, Ohio.
Correspondence to George E. Billman, PhD, Department of Physiology, The Ohio State University, 302 Hamilton Hall, 1645 Neil Ave, Columbus OH 43210-1218. E-mail billman.1{at}postbox.acs.ohio-state.edu
Background The ventricular myocardium contains functional ß2-adrenergic receptors that when activated increase intracellular Ca2+ transients. Because elevated Ca2+ has been implicated in the induction of ventricular fibrillation (VF), it is possible that the activation of these receptors may also provoke malignant arrhythmias.
Methods and Results To test this hypothesis, a 2-minute occlusion of the left circumflex coronary artery was made during the last minute of exercise in 28 dogs with healed anterior myocardial infarctions: 17 had VF (susceptible) and 11 did not (resistant). On a subsequent day, this test was repeated after administration of the ß2-adrenergic receptor antagonist ICI 118,551 (0.2 mg/kg). This drug did not alter the hemodynamic response to the coronary occlusion, yet it prevented VF in 10 of 11 animals tested (P<.001). However, heart rate was reduced in 6 animals. Therefore, the ICI 118,551 exercise-plus-ischemia test was repeated with heart rate held constant by ventricular pacing (n=3). ICI 118,551 still prevented VF when heart rate was maintained. Next, the effects of increasing doses of the ß2-adrenergic receptor agonist zinterol on Ca2+ transient amplitudes were examined in ventricular myocytes. Zinterol elicited significantly greater increases in Ca2+ transient amplitudes at all doses tested (10-9 to 10-6 mol/L) in myocytes prepared from susceptible versus resistant animals. The cardiomyocyte response to isoproterenol (10-7 mol/L) in the presence or absence of the selective ß1- (CGP-20712A, 300 nmol/L) or ß2- (ICI 118,551, 100 nmol/L) adrenergic receptor antagonist was also examined. Isoproterenol elicited larger Ca2+ transient increases in the susceptible myocytes, which were eliminated by ICI but not by CGP.
Conclusions When considered together, these data demonstrate that canine myocytes contain functional ß2-adrenergic receptors that are activated to a greater extent in the susceptible animals. The resulting cytosolic Ca2+ transient increases may lead to afterpotentials that ultimately trigger VF in these animals.
Key Words: cells • death, sudden • myocardial ischemia • receptors, adrenergic, beta
This article has been cited by other articles:
 |
|
 |
|
  J. DeSantiago, X. Ai, M. Islam, G. Acuna, M. T. Ziolo, D. M. Bers, and S. M. Pogwizd Arrhythmogenic Effects of {beta}2-Adrenergic Stimulation in the Failing Heart Are Attributable to Enhanced Sarcoplasmic Reticulum Ca Load Circ. Res., June 6, 2008; 102(11): 1389 - 1397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Holycross, M. Kukielka, Y. Nishijima, R. A. Altschuld, C. A. Carnes, and G. E. Billman Exercise training normalizes beta-adrenoceptor expression in dogs susceptible to ventricular fibrillation Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H2702 - H2709. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Maffei, A. Di Pardo, R. Carangi, P. Carullo, R. Poulet, M. T. Gentile, C. Vecchione, and G. Lembo Nebivolol Induces Nitric Oxide Release in the Heart Through Inducible Nitric Oxide Synthase Activation Hypertension, October 1, 2007; 50(4): 652 - 656. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Billman, M. Kukielka, R. Kelley, M. Moustafa-Bayoumi, and R. A. Altschuld Endurance exercise training attenuates cardiac beta2-adrenoceptor responsiveness and prevents ventricular fibrillation in animals susceptible to sudden death Am J Physiol Heart Circ Physiol, June 1, 2006; 290(6): H2590 - H2599. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sotoodehnia, D. S. Siscovick, M. Vatta, B. M. Psaty, R. P. Tracy, J. A. Towbin, R. N. Lemaitre, T. D. Rea, J. P. Durda, J. M. Chang, et al. {beta}2-Adrenergic Receptor Genetic Variants and Risk of Sudden Cardiac Death Circulation, April 18, 2006; 113(15): 1842 - 1848. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Billman and M. Kukielka Effects of endurance exercise training on heart rate variability and susceptibility to sudden cardiac death: protection is not due to enhanced cardiac vagal regulation J Appl Physiol, March 1, 2006; 100(3): 896 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Molenaar, T. Christ, U. Ravens, and A. Kaumann Carvedilol blocks {beta}2- more than {beta}1-adrenoceptors in human heart Cardiovasc Res, January 1, 2006; 69(1): 128 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dorian Antiarrhythmic Action of{beta}-Blockers: Potential Mechanisms Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2005; 10(4_suppl): S15 - S22. [Abstract] [PDF]
|
|
|
|
 |
|
 E. M. Kallergis, E. G. Manios, E. M. Kanoupakis, S. E. Schiza, H. E. Mavrakis, N. K. Klapsinos, and P. E. Vardas Acute Electrophysiologic Effects of Inhaled Salbutamol in Humans Chest, June 1, 2005; 127(6): 2057 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Masters and J. S. Stevenson A Theoretical Model of the Role of Brain Stem Nuclei in Alcohol-Mediated Arrhythmogenesis in Older Adults Biol Res Nurs, January 1, 2003; 4(3): 218 - 231. [Abstract] [PDF]
|
|
|
|
|
|
G. E. Billman Aerobic exercise conditioning: a nonpharmacological antiarrhythmic intervention J Appl Physiol, February 1, 2002; 92(2): 446 - 454. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Houle, R. A. Altschuld, and G. E. Billman Enhanced in vivo and in vitro contractile responses to {beta}2-adrenergic receptor stimulation in dogs susceptible to lethal arrhythmias J Appl Physiol, October 1, 2001; 91(4): 1627 - 1637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z.-S. Zhang, H.-J. Cheng, T. Ukai, H. Tachibana, and C.-P. Cheng Enhanced Cardiac L-Type Calcium Current Response to beta 2-Adrenergic Stimulation in Heart Failure J. Pharmacol. Exp. Ther., July 1, 2001; 298(1): 188 - 196. [Abstract] [Full Text]
|
|
|
|
 |
|
 M D Lowe, E Rowland, M J Brown, and A A Grace {beta}2 Adrenergic receptors mediate important electrophysiological effects in human ventricular myocardium Heart, July 1, 2001; 86(1): 45 - 51. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Kaye, L. Johnston, G. Vaddadi, H. Brunner-LaRocca, G. L. Jennings, and M. D. Esler Mechanisms of Carvedilol Action in Human Congestive Heart Failure Hypertension, May 1, 2001; 37(5): 1216 - 1221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Molenaar, S. Bartel, A. Cochrane, D. Vetter, H. Jalali, P. Pohlner, K. Burrell, P. Karczewski, E.-G. Krause, and A. Kaumann Both {beta}2- and {beta}1-Adrenergic Receptors Mediate Hastened Relaxation and Phosphorylation of Phospholamban and Troponin I in Ventricular Myocardium of Fallot Infants, Consistent With Selective Coupling of {beta}2-Adrenergic Receptors to Gs-Protein Circulation, October 10, 2000; 102(15): 1814 - 1821. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Exner, J. A. Reiffel, A. E. Epstein, R. Ledingham, M. J. Reiter, Q. Yao, H. J. Duff, D. Follmann, E. Schron, H. L. Greene, et al. Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: the antiarrhythmics versus implantable defibrillators (AVID) trial J. Am. Coll. Cardiol., August 1, 1999; 34(2): 325 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Exner, D. L. Dries, M. A. Waclawiw, B. Shelton, and M. J. Domanski Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a post hoc analysis of the studies of left ventricular dysfunction J. Am. Coll. Cardiol., March 15, 1999; 33(4): 916 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lechat, M. Packer, S. Chalon, M. Cucherat, T. Arab, and J.-P. Boissel Clinical Effects of ß-Adrenergic Blockade in Chronic Heart Failure : A Meta-Analysis of Double-Blind, Placebo-Controlled, Randomized Trials Circulation, September 22, 1998; 98(12): 1184 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. E. Billman, H. C. Englert, and B. A. Schölkens HMR 1883, a Novel Cardioselective Inhibitor of the ATP-Sensitive Potassium Channel. Part II: Effects on Susceptibility to Ventricular Fibrillation Induced by Myocardial Ischemia in Conscious Dogs J. Pharmacol. Exp. Ther., September 1, 1998; 286(3): 1465 - 1473. [Abstract] [Full Text]
|
|